Skip to main content
. 2025 Aug 21;12(2):e003490. doi: 10.1136/openhrt-2025-003490

Figure 5. Injection site adverse effects caused by subcutaneous injections periodically were statistically increased in the PCSK-9 targeting therapies group when compared with the control group (p<0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; M-H, Mantel-Haenszel; RCT, randomised controlled trial.

Figure 5